trial

Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine

NCTId NCT00315081
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 20
Sponsored by University Hospital, Bonn
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
20
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2006-05
Primary completion
—
Eligibility
MALE · 18 Years · 60 Years

Interventions & indications

Drugs
Bromocriptin

Sponsors

University Hospital, BonnLead Sponsor

Investigators

1
Wolfgang Maier, Prof. Dr.Principal Investigator

Sites

1 total
Bonn, Germany

Facts & assertions

3 sourced
Enrollment
20
Phase
PHASE3
Status
UNKNOWN
relationships
The graph out of here
drug
Bromocriptin
drug
lead_sponsor
University Hospital, Bonn
company
indication
Schizophrenia
indication
Schizophrenia
indication
Hyperprolactinemia
indication
investigator
Wolfgang Maier, Prof. Dr.
person